Published: January 2017
Roots Analysis has announced the addition of the “Prefilled Syringes Market (4th Edition), 2017-2026” report to its list of offerings. The report provides a comprehensive analysis of the current state and the likely future evolution of the prefilled syringes market. It provides details on key players, target disease indications, and the therapeutic classes of drugs that are available in the form of prefilled syringes.
Pemba Lahmo, the principal analyst, said, “Owing to their numerous benefits over conventional delivery systems, prefilled syringes have become indispensable in the medical field. This is evident from our research in which we identified a large number of vaccines, anticoagulants, multiple sclerosis drugs, anti-arthritic drugs, anti-anemic drugs, and drugs from other classes being administered through prefilled syringes. In fact, these syringes have improved significantly over the years. Manufacturers have recently developed multi-chamber syringes for use with lyophilized drugs. Such syringes are also being integrated with advanced injection devices, such as autoinjectors and pen injectors. In addition, prefilled diluent syringes and flush syringes are already quite popular. With more than 60% of candidate drugs / therapies in the clinical pipeline being biologics that usually require parenteral administration, the adoption of prefilled syringes is anticipated to further increase in the mid-long term”
Among other things, the report includes the following:
Lahmo further added, “The evolution of the prefilled syringes market in the long-term will be fueled by pipeline drugs, technological advances, and the rising adoption in developing markets. The global prefilled syringes market is likely to grow at an annualized rate of 3.9% between 2016 and 2026. A major share of prefilled syringes market is currently divided between North America (35%) and the EU (45%). However, in the coming decade, the prefilled syringes markets in Asia, Latin America, the Middle East and Africa are likely to grow at faster rate than those of the more developed regions.”
The 525 page report includes detailed profiles and assessment of the product portfolio of many global and regional companies. The opinions and insights presented in this study were influenced by discussions conducted with experts in this field. These included contributions from Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical Services), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), and Rondald Wheet (Chief Executive Officer, Revolutions Medical).
For additional details, please visit
About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at email@example.com
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES